Skip to Content

Nefecon FDA Approval Status

FDA Approved: No
Brand name: Nefecon
Generic name: budesonide
Company: Calliditas Therapeutics AB
Treatment for: Nephropathy

Nefecon (budesonide) is an oral, targeted release formulation of the approved anti-inflammatory corticosteroid budesonide in development for the treatment of primary IgA nephropathy (IgAN).

Development Timeline for Nefecon

DateArticle
Mar 15, 2021Calliditas Announces Submission of New Drug Application to U.S. FDA for Nefecon in Patients with Primary IgA Nephropathy

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.